Cargando…

Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant

Pegvisomant monotherapy is effective and safe in treatment of acromegaly. However, some clinicians combine pegvisomant with somatostatin analogues (SSA) or dopamine agonist (DA). In this analysis of ACROSTUDY, a long-term non-interventional study, the use of combination regimens was evaluated. Based...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strasburger, Christian J, Mattsson, Anders, Wilton, Patrick, Aydin, Ferah, Hey-Hadavi, Judith, Biller, Beverly M K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2018
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863474/ https://www.ncbi.nlm.nih.gov/pubmed/29371335 http://dx.doi.org/10.1530/EJE-17-0996

Ejemplares similares

Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy
por: Brue, Thierry, et al.
Publicado: (2018)

More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY
por: Fleseriu, Maria, et al.
Publicado: (2021)

Pegvisomant in acromegaly: an update
por: Giustina, A., et al.
Publicado: (2017)

Nanomedicines in the treatment of acromegaly: focus on pegvisomant
por: Roelfsema, Ferdinand, et al.
Publicado: (2006)

Pegvisomant for acromegaly: does it always works?
por: Neggers, Sebastian J., et al.
Publicado: (2019)

SUN-LB080 ACROSTUDY - Safety and Efficacy of a Cohort of 110 Naïve Patients with Acromegaly Treated with Pegvisomant
por: Wajnrajch, Michael, et al.
Publicado: (2019)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

Brazilian multicenter study on pegvisomant treatment in acromegaly
por: Boguszewski, Cesar L., et al.
Publicado: (2019)

SUN-LB079 Acrostudy - Safety And Treatment Outcomes In 2221 Patients With Acromegaly Treated With Pegvisomant: Real World Experience
por: Wajnrajch, Michael, et al.
Publicado: (2019)

Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study
por: Kuhn, Emmanuelle, et al.
Publicado: (2015)

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline
por: Giustina, A., et al.
Publicado: (2014)

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
por: Neggers, Sebastian J. C. M. M., et al.
Publicado: (2011)

Body Composition Changes with Long-term Pegvisomant Therapy of Acromegaly
por: Kuker, Adriana P, et al.
Publicado: (2021)

Pegvisomant in acromegaly: a multicenter real-life study in Argentina
por: Basavilbaso, Natalia Ximena Garcia, et al.
Publicado: (2019)

Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

Hypertension in Acromegaly in Relationship to Biochemical Control and Mortality: Global ACROSTUDY Outcomes
por: Vila, Greisa, et al.
Publicado: (2020)

Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY
por: Grottoli, S., et al.
Publicado: (2022)

Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation
por: Moore, David J, et al.
Publicado: (2009)

Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
por: Ma, Lingyun, et al.
Publicado: (2020)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

OR23-06 Is the Improved Glucose Homeostasis in Patients with Acromegaly Treated with Pegvisomant Caused by Improved Glucagon Secretion?
por: Jørgensen, miss, Nanna Thurmann, et al.
Publicado: (2020)

Difficulties in diagnosing acromegaly, acromegaly with apparently normal GH: Micromegaly
por: Demir, Ahmet Numan, et al.
Publicado: (2023)

Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response
por: Kasuki, Leandro, et al.
Publicado: (2016)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

A Pituitary Society update to acromegaly management guidelines
por: Fleseriu, Maria, et al.
Publicado: (2020)

SAT-444 Pituitary Function and the Response to GH Replacement Therapy in Patients with Histiocytosis: Analysis of the Pfizer International Metabolic Database (KIMS)
por: Touraine, Philippe, et al.
Publicado: (2019)

Clinical and radiological evidence of the recurrence of reversible pegvisomant-related lipohypertrophy at the new site of injection in two women with acromegaly: a case series
por: Rochira, Vincenzo, et al.
Publicado: (2012)

Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience
por: Pirchio, R., et al.
Publicado: (2023)

Pituitary function and the response to GH therapy in patients with Langerhans cell histiocytosis: analysis of the KIMS database
por: Touraine, Philippe, et al.
Publicado: (2022)

Neurocognitive Function in Acromegaly after Surgical Resection of GH-Secreting Adenoma versus Naïve Acromegaly
por: Martín-Rodríguez, Juan Francisco, et al.
Publicado: (2013)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

Atypical Course of a Patient With AIP-Positive Acromegaly: From GH Excess to GH Deficiency and Back to GH Excess
por: García-de-la-Torre, Keren-Sandyn, et al.
Publicado: (2023)

Safety and Efficacy of Pegvisomant in Pediatric Growth Hormone Excess
por: Tatsi, Christina, et al.
Publicado: (2021)

GH Secretory Dynamics and Responsiveness to SMS 201-995 Treatment in Acromegaly
por: Kim, Sung Woon, et al.
Publicado: (1988)

Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas
por: Biller, Beverly MK, et al.
Publicado: (2010)

Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly
por: Strasburger, Christian J, et al.
Publicado: (2016)

THU050 The Role Of The GH Receptor Polymorphism As Prognostic Factor Of Vertebral Fractures In Acromegaly Patients Resistant To First Generation SSAs And Treated With GH Receptor Antagonist Or Second Generation Somatostatin Ligand
por: Costanza, Flavia, et al.
Publicado: (2023)

GH, IGF-1, and Age Are Important Contributors to Thyroid Abnormalities in Patients with Acromegaly
por: Wu, Xia, et al.
Publicado: (2018)

Surgical Remission of Acromegaly Resolves Neuroglycopenia and Paradoxical Rise in GH after OGTT
por: Magar, Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5l1achhes1ad3t41qff89k4gup